Brief: Sellas Announces U.S. FDA Rare Pediatric Disease Designation Granted To SLS009 For The Treatment Of Pediatric Acute Lymphoblastic Leukemia
24/06/2024 15:46
June 24 (Reuters) - Sellas Life Sciences Group Inc
SLS.O :
* SELLAS ANNOUNCES U.S. FDA RARE PEDIATRIC DISEASE
DESIGNATION
GRANTED TO SLS009 FOR THE TREATMENT OF PEDIATRIC ACUTE
LYMPHOBLASTIC LEUKEMIA
Source text for Eikon: ID:nGNX1KYcxW
Further company coverage: SLS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses